Does SelectHealth Cover Prolia (Denosumab)? A Complete Insurance Guide

What Is Prolia and Why Does Coverage Get Complicated?

Prolia is the brand name for denosumab, a fully human monoclonal antibody that inhibits RANK ligand, blocking osteoclast formation and reducing bone resorption. The FDA approved denosumab 60 mg subcutaneous every 6 months for postmenopausal osteoporosis in June 2010, then expanded approval to include men with osteoporosis, glucocorticoid-induced osteoporosis, and bone loss from hormone-ablation therapy in oncology settings. [1]

Because Prolia carries a list price near $1,400 per dose, insurers including SelectHealth place it on specialty drug tiers and require prior authorization before dispensing. The clinical evidence base for Prolia is large and well-established. The FREEDOM trial (N=7,808) showed denosumab reduced new vertebral fractures by 68% over 36 months versus placebo (relative risk 0.32 to 95% CI 0.26-0.41, P<0.001) in postmenopausal women with T-scores between -2.5 and -4.0. [2] The same trial showed a 40% reduction in hip fracture risk (P=0.04). [2]

SelectHealth operates as the health insurance arm of Intermountain Health, serving members primarily in Utah, Idaho, and Nevada. Its formulary decisions are reviewed annually and can differ between commercial, Medicaid managed care, and Medicare Advantage products. [3]

Understanding the pathway from prescription to paid claim requires knowing how SelectHealth classifies the drug, what prior authorization (PA) criteria are applied, and what options exist when coverage is denied.

How SelectHealth Classifies Prolia on Its Formulary

SelectHealth places Prolia on a specialty drug tier on most of its commercial and Medicare Advantage plans. Specialty tiers typically carry the highest cost-sharing, often 20-33% coinsurance rather than a flat copay, which on a $1,400 injection translates to $280-$462 per dose out of pocket before any assistance programs.

The drug is covered under the pharmacy benefit on some plans and under the medical benefit on others, depending on how it is administered. When a clinician administers the injection in-office (the most common scenario for Prolia), it routes through the medical benefit under HCPCS code J0897. When dispensed through a specialty pharmacy for patient self-administration, it routes through the pharmacy benefit. [4] The benefit bucket matters because your deductible, out-of-pocket maximum, and cost-sharing percentages may differ between medical and pharmacy benefits within the same plan.

Checking SelectHealth's posted formulary at selecthealth.org or calling the member services number on your insurance card will confirm the current tier placement for the plan year. Formularies are updated annually on January 1 and may change mid-year for newly approved biosimilars.

The FDA approved the first denosumab biosimilar, Jubbonti and Wyost (Samsung Bioepis/Organon), in March 2024, and a second biosimilar Osenvelt (Fresenius Kabi) in June 2024. [5] SelectHealth may shift formulary preference to a lower-cost biosimilar, which could affect PA criteria for brand-name Prolia starting in 2025 plan years. Asking your prescriber specifically whether SelectHealth now prefers a biosimilar denosumab is a practical first step.

Prior Authorization Criteria SelectHealth Typically Applies

Prior authorization for Prolia at SelectHealth is not discretionary. PA is required across virtually all plan types. The specific clinical criteria are outlined in SelectHealth's clinical coverage criteria documents, which are publicly available and updated annually. [6]

Based on standard insurer criteria for denosumab and guidelines from the American Association of Clinical Endocrinologists (AACE) and the Endocrine Society, SelectHealth's PA requirements generally include the following elements:

Diagnosis confirmation. The prescriber must document a diagnosis of postmenopausal osteoporosis, male osteoporosis, glucocorticoid-induced osteoporosis, or an applicable oncology indication (prostate or breast cancer patients on hormone-ablation therapy with bone loss). ICD-10 codes M81.0 (age-related osteoporosis without current pathological fracture) or M80-series codes for fracture-related osteoporosis are the relevant diagnostic anchors. [7]

Bone mineral density documentation. A DEXA scan showing a T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip is the standard threshold. Some plans accept a T-score between -1.0 and -2.5 (osteopenia range) if a documented fragility fracture is present or if the FRAX 10-year fracture probability exceeds the National Osteoporosis Foundation threshold of 3% for hip or 20% for major osteoporotic fracture. [8]

Prior therapy documentation. Many SelectHealth PA decisions require evidence that the patient has tried, failed, or has a contraindication to first-line oral bisphosphonate therapy (alendronate, risedronate) before Prolia is authorized. This step-therapy requirement is common but not universal across all SelectHealth plan types. Patients who are unable to tolerate bisphosphonates due to upper GI adverse effects or renal impairment (estimated GFR <35 mL/min/1.73m2, where bisphosphonates are generally contraindicated) may qualify without a prior bisphosphonate trial. [9]

Prescriber specialty. Some PA forms request prescriber information. Prolia is frequently prescribed by endocrinologists, rheumatologists, and gynecologists, all of whom SelectHealth recognizes as appropriate prescribers for this indication.

The AACE 2020 osteoporosis guidelines state: "Denosumab is recommended as a first-line agent for postmenopausal women with osteoporosis who are at very high fracture risk, including those with a prior hip or vertebral fracture." [10] This guideline language is directly relevant to PA appeals, because it supports denosumab use without requiring a prior bisphosphonate trial in high-risk patients.

Step-Therapy Requirements: When SelectHealth Demands a Bisphosphonate First

Step therapy is a coverage policy that requires patients to try less expensive drugs before a more costly option is approved. SelectHealth applies step therapy to Prolia on commercial and some Medicare Advantage plans.

Alendronate 70 mg weekly is the most common required first step, given its generic availability and cost near $10-$30 per month. Risedronate 35 mg weekly or 150 mg monthly is sometimes listed as an acceptable alternative first step. [11]

The clinical basis for step therapy is debated among bone specialists. A meta-analysis published in JAMA Internal Medicine (2019) covering 23 randomized trials found that bisphosphonates reduce vertebral fracture risk by approximately 40-70% depending on the agent, making them genuinely effective first-line options for most patients. [12] However, for patients at very high fracture risk, such as those with a prior hip fracture or T-score below -3.0, delaying Prolia in favor of a bisphosphonate trial has clinical costs.

Utah's step-therapy law (Utah Code Annotated 31A-22-652), enacted in 2018, requires insurers operating in Utah to grant exceptions to step-therapy requirements when a physician documents that the required drug is contraindicated, previously failed, or likely to cause adverse effects. [13] SelectHealth is domiciled in Utah and must comply with this law on its commercial products.

Documenting a step-therapy exception requires your prescriber to submit a letter of medical necessity explaining specifically why bisphosphonate therapy is not appropriate, referencing your clinical history, GFR if relevant, or prior GI adverse events.

How to Submit a Prolia Prior Authorization to SelectHealth

The PA process typically follows these steps:

Your prescriber's office initiates the PA request, either through SelectHealth's provider portal, by fax, or via a clearinghouse like CoverMyMeds. The PA form requires the patient's SelectHealth member ID, the prescribing provider's NPI, the drug name and dose, the ICD-10 diagnosis code, the most recent DEXA scan result (T-score and date), and clinical notes supporting medical necessity.

SelectHealth must respond to standard PA requests within 3 business days under Utah insurance regulations and within 72 hours for urgent requests. [14] Specialty pharmacy PA requests may have slightly different timelines depending on the dispensing pathway.

If the PA is approved, SelectHealth will issue an authorization number valid for a defined period (commonly 6-12 months). Because Prolia is given every 6 months, most approved PAs cover two injections per authorization period.

Submit the DEXA scan report, the prescriber's clinical notes, any documentation of prior bisphosphonate use or intolerance, and the ICD-10 code at the same time as the PA form. Missing documentation is the most common reason for initial denial.

What to Do If SelectHealth Denies Prolia Coverage

Denials for Prolia at SelectHealth most commonly cite one of three reasons: the patient did not complete required step therapy, the DEXA T-score does not meet threshold, or documentation was insufficient.

Each reason has a specific response strategy.

Denial for step-therapy non-completion. File an exception request under Utah's step-therapy law, supported by a letter of medical necessity from your prescriber. Reference the AACE 2020 guideline recommendation that denosumab is first-line for very-high-risk patients. [10] Attach any documentation of bisphosphonate intolerance (pharmacy records of fills plus prescriber notes about adverse effects).

Denial for T-score not meeting threshold. Ask your prescriber to include FRAX 10-year fracture probability in the appeal documentation. A FRAX hip fracture probability above 3% or major fracture probability above 20% supports treatment at T-scores in the osteopenia range, per National Osteoporosis Foundation guidelines. [8] Including a fragility fracture history (wrist, hip, vertebral, or rib fracture from minimal trauma) significantly strengthens an appeal.

Denial for insufficient documentation. Resubmit with the complete medical record including the DEXA scan report, relevant office visit notes, and any laboratory results (serum creatinine, vitamin D level, calcium). SelectHealth's appeals address and fax number appear on the denial letter; use those contacts specifically rather than general member services.

Federal law under the ACA gives you the right to an internal appeal within 180 days of a denial and an external appeal through an independent review organization if the internal appeal fails. [14] Utah also allows external review through the Utah Insurance Department. External review overturns specialty drug denials in roughly 40-60% of cases when complete clinical documentation is submitted.

Prolia Coverage Under SelectHealth Medicare Advantage Plans

SelectHealth offers Medicare Advantage plans in Utah marketed under the SelectHealth Medicare Advantage portfolio. Coverage of Prolia under these plans follows the Medicare Part B and Part D frameworks, depending on how the drug is administered.

When Prolia is administered by a physician or qualified healthcare professional in an office or clinic setting, Medicare (and Medicare Advantage) covers it under Part B as an injectable drug. The patient's Part B cost-sharing applies (typically 20% after the Part B deductible under traditional Medicare, though Medicare Advantage plans may set different cost-sharing). [15]

When dispensed through a specialty pharmacy, it falls under Part D, where plan formularies apply. The Inflation Reduction Act of 2022 capped Medicare Part D out-of-pocket drug spending at $2,000 per year starting January 1, 2025, which substantially reduces Prolia's annual cost for Medicare patients on Part D. [16]

SelectHealth's Medicare Advantage plans are required to cover drugs that Medicare covers under Part B without imposing step-therapy restrictions on Part B drugs per CMS guidance. Step-therapy policies apply only to Part D medications under Medicare rules. [17]

Prolia Cost Assistance When Coverage Is Denied or Cost-Sharing Is High

Amgen, Prolia's manufacturer, operates the Prolia Assist patient support program. Commercially insured patients with out-of-pocket costs above a threshold may receive copay assistance. Uninsured or underinsured patients may qualify for free drug through Amgen's patient assistance program. Eligibility is income-based for free drug programs; commercially insured patients with any income level may access copay cards reducing out-of-pocket to as low as $0 per dose.

The program is accessible at prolia.com/support or by calling Amgen's support line. Amgen's patient assistance does not apply to patients with Medicare or Medicaid as their primary coverage, per federal anti-kickback statute exclusions.

NeedyMeds and RxAssist maintain independent databases of patient assistance programs for denosumab and may list additional state-level programs for Utah residents.

If a biosimilar denosumab is substituted by SelectHealth's formulary, patient assistance programs from the biosimilar manufacturer (Samsung Bioepis or Fresenius Kabi) may apply. Confirm the specific biosimilar on your plan's formulary before contacting manufacturer assistance programs.

Clinical Evidence Supporting Prolia's Place in Osteoporosis Treatment

Coverage decisions by SelectHealth are informed partly by the clinical evidence base. Reviewers evaluating PA requests look for alignment between a patient's clinical profile and the evidence supporting the drug's use.

The FREEDOM Extension study followed patients from the original FREEDOM trial for up to 10 years of denosumab treatment. Patients who received denosumab continuously for 10 years showed sustained 21.7% gain in lumbar spine BMD and 9.2% gain in total hip BMD from baseline, with no evidence of an increase in fracture rate over time. [18] This long-term data distinguishes denosumab from bisphosphonates, which carry concerns about atypical femoral fractures and osteonecrosis of the jaw with very prolonged use.

The Endocrine Society's 2019 clinical practice guideline on pharmacological management of osteoporosis in postmenopausal women identifies denosumab as a first-line option for women at high fracture risk. [19] The guideline states: "Denosumab reduces the risk of vertebral, nonvertebral, and hip fractures and can be used as initial pharmacological therapy."

One critical clinical consideration: discontinuing denosumab without transitioning to a bisphosphonate causes rapid bone mineral density loss and a rebound increase in vertebral fracture risk, sometimes called the "rebound phenomenon." A study published in the Journal of Bone and Mineral Research (2017, N=1,001) found that 7.1% of patients who discontinued denosumab without sequential therapy suffered vertebral fractures within 12 months of the last dose. [20] SelectHealth's PA approval duration (typically 12 months for two doses) must be renewed; a lapse in coverage requires urgent prescriber action to either secure continued Prolia authorization or transition to a bisphosphonate.

The RANK ligand pathway that denosumab inhibits is also the target of biosimilar competition. With FDA-approved biosimilars now available, clinical guidelines from the American Society for Bone and Mineral Research acknowledge biosimilar denosumab as therapeutically equivalent for fracture prevention. [21]

How Glucocorticoid-Induced Osteoporosis Changes the Coverage Picture

Patients taking prednisone 7.5 mg/day or equivalent for 3 or more months face accelerated bone loss. The American College of Rheumatology (ACR) 2022 guideline on glucocorticoid-induced osteoporosis recommends Prolia for moderate-to-high fracture risk patients on chronic glucocorticoids when oral bisphosphonates are not appropriate. [22]

SelectHealth's PA criteria for glucocorticoid-induced osteoporosis typically require documentation of chronic glucocorticoid use (dose and duration), a DEXA scan, and FRAX-based fracture risk assessment incorporating glucocorticoid use. The ACR guideline uses a FRAX 10-year major fracture probability of 10% or greater as the threshold for pharmacological treatment in glucocorticoid users, lower than the NOF threshold for postmenopausal osteoporosis. [22]

Prescribers submitting PA requests for glucocorticoid-induced osteoporosis should include the glucocorticoid medication name, dose, and duration, along with the most recent DEXA and FRAX calculation. This documentation directly maps to SelectHealth's PA clinical criteria for this indication.

Oncology Indications: Bone Loss from Hormone-Ablation Therapy

Men with prostate cancer receiving androgen deprivation therapy (ADT) and women with breast cancer receiving aromatase inhibitor (AI) therapy are at high risk for accelerated bone loss and fracture. The FDA-approved indication for Prolia 60 mg every 6 months covers bone loss in these patients. [1]

In the HALT trial (N=1,468), denosumab 60 mg every 6 months significantly increased lumbar spine BMD by 5.6% at 24 months versus a 1.0% loss in the placebo group in men on ADT for nonmetastatic prostate cancer (P<0.001). [23] SelectHealth's oncology PA pathway for Prolia generally requires documentation of the primary cancer diagnosis, current hormone-ablation therapy, and baseline bone density.

Oncology patients should confirm whether the Prolia claim routes through the medical benefit (oncology drug administration) or pharmacy benefit on their specific SelectHealth plan, since oncology drug billing pathways can differ from standard medical drug administration.

Practical Action Checklist Before Your First Prolia Injection

Before the first injection, complete a DEXA scan and ensure the written report with T-scores is in your medical record. Ask your prescriber to confirm the ICD-10 diagnosis code and FRAX probability. Verify your SelectHealth plan's formulary tier for Prolia or its biosimilar equivalents by calling member services or reviewing the annual notice of change document.

Request that your prescriber's office submit the PA at least 10-15 business days before the planned injection date, allowing time for initial review and a potential appeal. Ask for the PA tracking number so you can follow up.

If your plan routes Prolia through the pharmacy benefit, identify your SelectHealth-contracted specialty pharmacy in advance. Prolia requires refrigeration and cannot be dispensed through standard retail pharmacies.

Once the first PA is approved, set a calendar reminder 60 days before the 6-month mark to initiate PA renewal, since many SelectHealth PAs require annual or semi-annual reauthorization.

Contact Amgen at 1-800-772-6436 to enroll in Prolia Assist before your first dose if your estimated out-of-pocket cost exceeds $200 per injection after insurance.